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Potentially inappropriate prescribing in dementia, 
multimorbidity and incidence of adverse health outcomes 
  
Key Points  
Individuals with dementia are at risk of potentially inappropriate prescribing (PIP), however, 
its impact on this population is unknown.  
Using primary care records we investigated the effect of PIP in 11,175 individuals with 
dementia aged over 65 years in 2016 and 43,463 controls matched on age and gender.  
Screening-Tool-of-Older-Persons'-Prescriptions V2 defined PIP. 
At 73% prevalence, in individuals with dementia have higher risk of PIP. 
PIP was associated with increased risk of all-cause mortality, skin ulcer and pressure sores, 
falls, anaemia and osteoporosis. 
Keywords 




Importance: Treatment of dementia in individuals with comorbidities is complex, leading to 
potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. 
Objective: Estimate the rate of PIP and its effect on adverse health outcomes (AHO). 
Design: Retrospective cohort. 
Setting: Primary Care Electronic Health Records linked to hospital discharge data from 
England. 
Subjects: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age and 
sex matched controls. 
Methods: Screening-Tool-of-Older-Persons'-Prescriptions-V2 defined PIP. Logistic regression 
tested associations with comorbidities at baseline, and survival analyses risk of incident 
AHO, adjusted for age, gender, deprivation and 14 comorbidities. 
Results: The dementia group had increased risk of PIP (73% prevalence; odds-ratio 1.92 
confidence-interval CI 83-103%, p <0.01) after adjusting for comorbidities. Most frequent 
PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP 
was higher in patients also diagnosed with coronary-heart disease (odds-ratio 2.17 CI 1.91-
2.46 p <0.01), severe mental illness (odds-ratio 2.09 CI 1.62-2.70 p <0.01); and depression 
(odds-ratio 1.81 CI 1.62-2.01 p <0.01).  
During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard-
ratio 1.14 CI 1.02-1.26 p 0.02), skin ulcer and pressure sores (hazard-ratio 1.66 CI 1.12-2.46 
p 0.01), falls (hazard-ratio 1.37 CI 1.15-1.63 p<0.01), anaemia (hazard-ratio 1.61 CI1.10-2.38 
p 0.02) and osteoporosis (hazard-ratio 1.62 CI1.02-2.57 p 0.04). 
Conclusion: Patients with dementia frequently receive PIPs, and those that do are more 
likely to experience AHO. These results highlight the need to optimise medication in 
dementia patients, especially those with comorbidities. 
  
Background 
Dementia includes irreversible neurological conditions  affecting 2-3% of 65yr olds, and 30-
50% at 85 plus.1,2 These conditions include Alzheimer’s dementia (AD), vascular dementia 
(VaD), Parkinson’s dementia, frontotemporal dementia and other rarer forms.3,4 
Dementia diagnosis frequently occurs with comorbidities, complicating clinical 
management,5,6 Individuals diagnosed with dementia are prescribed on average 5 to 10 
medications at any one time.7,8 High prescription rates place patients at risk of potentially 
inappropriate prescribing (PIP).9 PIP refers to the use of medications when safer alternatives 
exist.10 PIP is associated with increased risk of adverse drug events, hospitalisation and 
death, plus reductions in quality of life, and declines in intellectual function.11,12 
People living with dementia are at risk of PIP and by extension of adverse drug events.1,12 
However as people living with dementia are often excluded from longitudinal studies 
evidence of association with outcomes remains limited. Few studies have focussed on the 
management of multiple conditions in this population. Most recent estimates of PIP 
prevalence in people living with dementia use outdated criteria,13 and studies of the impact 
of PIP in health outcomes for people living with dementia are unavailable.12 
We used the Screening Tool of Older Persons' Prescriptions version 2 criteria (STOPP) to 
estimate prevalence of PIPs among people living with dementia, in UK primary care 
electronic health records.14 We compared this with prevalence in people without recorded 
dementia, matched on key characteristics. We focus on 3 overarching questions: 1) what is 
the prevalence of PIP in people living with dementia compared to those without recorded 
dementia of similar age and gender and accounting for comorbidities? 2) which factors (e.g. 
comorbidities of dementia) increase the risk of PIP? and 3) is PIP associated with adverse 
health outcomes for people living with a diagnosis of dementia? 
Methods 
The Clinical Practice Research Datalink (CPRD) includes primary care records for patients in 
the community, nursing or residential settings from 674 UK practices. Records include 
clinical symptoms, diagnoses and prescriptions recorded during routine clinical practice, and 
medical test results and participation in health prevention programmes. CPRD is broadly 
representative of the UK’s older population.15,16 We used CPRD linked to NHS Hospital 
Episode Statistics (HES) admission data and the UK government’s Office for National 
Statistics (ONS) death certificate register. 
Population 
This is a cohort analysis of individuals diagnosed with dementia before or on 1st January 
2016, the study start date (SSD). Individuals included were alive, aged ≥65 years, with 
records deemed of acceptable research quality (see supplemental material). Diagnosis of 
dementia were included at the earliest record of a diagnosis code in primary and secondary 
care records (diagnosis codes in supplemental material - eTable 1). The control group 
without recorded dementia met the same inclusion criteria. Controls were matched on year-
of-birth and gender, with 1 case for 4 controls. Individuals with young-onset dementia or 
rare forms of dementia including Creutzfeldt-Jakob disease, frontotemporal dementia, and 
Huntington's disease were excluded as these are distinct presentations with different 
treatment requirements (eTable 2).17 Deprivation status was based on individual postcode, 
and split into quintiles 18. Characterization of smoking, drinking habits and body mass index 
(BMI) described in supplemental material.  
Potentially inappropriate prescribing. 
PIP was identified in the lead-in period of 1 year before the SSD. Using prescription records, 
PIP was defined as the prescription of any combination of drugs deemed potentially harmful 
by STOPP/START version 2 criteria.14 This defines instances of PIP which may increase risks 
of adverse drug events, applied to a UK and European context. Version 2 of the STOPP 
criteria specifies errors by commission, better addressing issues of polypharmacy and has a 
demonstrable association with adverse drug events.19 We adapted the Bradley et al.20 
implementation of STOPP version 1 criteria in CPRD, updating it to version 2. The 
comprehensive prescription and clinical data available in CPRD allowed for operationalising 
56 of 80 defined criteria. 
Multimorbidity and comorbidities of dementia 
14 comorbidities were ascertained: atrial fibrillation, asthma, cancer, coronary heart 
disease, chronic kidney disease, chronic obstructive pulmonary disease, depression, 
diabetes mellitus, epilepsy, heart failure, hypertension, hypothyroidism, severe mental 
illness (psychosis, schizophrenia and bipolar disease causing hallucinations, delusions or 
catatonia) and stroke. We selected conditions included in the NHS Quality of outcomes 
Framework, an incentive payment programme that improved record keeping.15 For chronic 
conditions, the earliest recorded diagnosis code in primary or secondary health records 
before the SSD were accepted, and for cancer a diagnosis code recorded in the 5 years 
before the SSD. 
Adverse Health Outcomes 
Adverse health outcomes (AHO) studied included all cause-mortality, hospitalisation 
(planned and unplanned) and common conditions and syndromes of old age (delirium, 
anaemia, falls, fractures, incontinence, osteoarthritis, osteoporosis, peptic ulcer, and skin 
ulcer and pressure sores). Individuals were followed for one year, with AHO recorded as a 
binary variable at first occurrence during the follow-up period (one year after SSD).  
Statistical analysis 
Baseline data analyses produced estimates of PIP prevalence. Prevalence of each STOPP 
criterion with 95% confidence intervals (CIs), were calculated. Chi-square analyses tested for 
differences between dementia and control group. Logistic regression tested associations 
between PIP in people with dementia and the presence of a diagnosis of 14 chronic 
conditions. Survival analyses tested the association between PIP and AHO during 1 year of 
follow-up. Analyses compared individuals with at least one PIP criterion vs none, 3 or more 
PIP criteria vs none, and in individuals with 3 or more comorbidities. Cox proportional 
hazards regression model was used for the all-cause mortality, and Fine and Gray competing 
risk models - all-cause mortality as competing risk - for all other outcomes.21  All analyses 
were adjusted for age (squared), gender and quintiles of multiple deprivation, and 
diagnoses for 14 chronic conditions. Survival analyses were also adjusted for prior presence 
of target outcome. For all analyses statistical significance was set at p-value <0.05. All 
analyses were conducted using STATA Version 15 (Timberlake Consultants Ltd, London, UK). 
Sensitivity analyses were performed to test associations in the subgroup of individuals living 
in the community. Adjustments for drinking, smoking habits, BMI have the potential for 
confounding by reverse causation22, making it difficult to interpret estimates, thus these 
were added as a sensitivity analysis.  
Declaration of Sources of Funding  
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Results 
11,175 individuals diagnosed with dementia before SSD (average age: 84.4 years old, 63.9% 
female) were included in analyses, plus 43,463 matched controls (average age: 83.4 years, 
and 64.6% female) (Table 1). Cases were well matched with 99.1% matched with 3 or 4 
controls, and the remainder with 1 or 2 controls.   
A total of 8,211 individuals with dementia had at least one PIP according to the STOPP 
version 2 criteria (Table 2). Prevalence of PIP was higher in individuals diagnosed with 
dementia (73.5%) compared to individuals of similar age and gender without a record of 
dementia (57.0%). This difference between groups was statistically significant (OR) 1.92, 
95% confidence interval (CI) 1.83- 2.03 p <0.01) after adjusting for adjusting for age 
(squared), gender, quintiles of deprivation, and diagnosis of 14 chronic comorbidities. The 
increased PIP risk remained in individuals living in the community (OR 1.86 CI 1.76-1.96 p 
<0.01). 
In individuals with dementia, 11 out of the 56 criteria had prevalence greater than 5% 
(eTable 3), with the most common being: 1) anticholinergics/antimuscarinics in patients 
with delirium or dementia (46.1%); 2) any duplicate drug class prescription (optimisation of 
monotherapy within a single drug class) (31.5%); 3) non-Steroidal Anti-Inflammatory 
(NSAID) with severe hypertension or severe heart failure (22.5%). 
Prevalence of PIP in dementia by comorbidities  
In the dementia group prevalence of PIP increased with the number of comorbidities (0: 
39.3%, 1-2: 61.9%, 3-6: 82.1%, 7 or more PIP: 93.5%). Comorbidities associated with higher 
PIP prevalence were: coronary heart disease (OR 2.17 CI 1.91-2.46 p <0.01); severe mental 
illness (OR 2.09 CI1.62-2.70 p <0.01); depression (OR 1.81 CI 1.62-2.01 p<0.01); chronic 
obstructive pulmonary disease (OR 1.80 CI1.51-2.14 p <0.01); and hypertension (OR 1.67 
CI1.52-1.84 p <0.01) (Table 3). Conditions not associated with increased risk of PIP were 
epilepsy, hypothyroidism, a recent history of cancer, and asthma. 
Association of PIP and incidence of adverse health outcomes 
In the dementia group having at least one instance of PIP in the year prior to SSD was 
associated with incidence of all-cause mortality (hazard ratio (HR) 1.14 CI 1.02-1.26 p 0.02), 
skin ulcer and pressure sores (HR 1.66 CI 1.12-2.46 p 0.01), falls (HR 1.37 CI 1.15-1.63 p 
<0.01), anaemia (HR 1.61 CI 1.10-2.38 p 0.02) and osteoporosis (HR 1.62 CI 1.02-2.57 p 0.04) 
(Table 4). In individuals with 3 or more PIP, additional statistically significant associations 
were identified for at least one hospitalisation in the following year (HR 1.15 CI 1.05-1.25 p 
<0.01), delirium (HR 1.36 CI 1.06-1.74 p 0.02) and incontinence (HR 1.34 CI 1.01-1.78 p 0.04). 
Other tested outcomes such as fractures and peptic ulcer were not associated with 
instances of PIP (Table 4). Lastly, in individuals with 3 or more PIP and 3 or more 
comorbidities we found similar associations with AHO, although for all-cause mortality (HR 
1.08 CI 0.94-1.24 p 0.26) and incontinence (HR 1.25 CI 0.90-1.74 p 0.18) the associations 
were not significant. In a sensitivity analysis on a sub-sample of individuals living in the 
community, associations were little changed (eTable 4) although for all-cause mortality 
narrowly missed statistical significance (HR 1.11 CI 0.99-1.24 p 0.07). Sensitivity analyses 
with additional adjustments for drinking, smoking, BMI and years since dementia diagnosis 
demonstrated similar results (eTable 5), but the association with incontinence narrowly 
missed significance (OR 1.29 CI95 0.97-1.72 p. 0.07). 
Discussion 
This study provides estimates for PIP prevalence in a large, broadly representative sample of 
UK primary care patients living with a diagnosis of dementia, in 2016. PIP prevalence with 
dementia in the year before the 01 January 2016 was 73.4%; this is higher than previous 
comparable estimates, which ranged from 13.9% to 64.5% in different settings. Remarkably, 
people with a diagnosis of dementia were 83% to 103% more likely to have a recorded PIP 
than individuals of similar age and gender without a record of dementia, after accounting 
for 14 comorbidities and socio-economic deprivation. This is similar to previous findings of 
higher prevalence of PIP in people living with dementia.23,24 
Importantly, this study establishes for the first time an association between presence of PIP 
and increased risk of AHO for people living with dementia. Individuals with one or more PIP 
had increased mortality, plus increased rates of skin ulcer and pressure sores, falls and 
anaemia: higher risks of AHOs were present in those with ≥3 PIP, with additional association 
with hospital admissions, delirium and incontinence. The results did not meaningfully 
change when focussing on those living in the community or when adjusting for lifestyle, 
body composition and years living with dementia (eTable 4 & 5). Studies investigating PIP in 
people with dementia have mainly focused on the prevalence and risk factors of PIP,24 while 
studies of PIP impacts on mortality and morbidity in this group are  unavailable.12 Our study 
demonstrates that PIP is associated with a real increase in health risks to people living with 
dementia, further supporting the case for improving medication management in this group. 
Medical conditions in older individuals with dementia are commonly managed 
pharmacologically, and optimisation of medication remains a challenge.25 Management of 
co-morbidities is likely a contributor to the high prevalence of PIP in people living with 
dementia. The two most frequent PIP criteria include: therapeutic duplication, which is 
closely associated with treatment of multiple conditions, and has been described as “caused 
by poor communication between different physicians”;26 and prescription of 
anticholinergic/antimuscarinic drugs in patients with delirium or dementia, drugs commonly 
used to treat some dementia symptoms (i.e. sedatives) but also to treat co-morbidities of 
dementia, including cardiovascular disease (i.e. anti-arrhythmic) and incontinence (i.e. anti-
muscarinic drugs).27 
Evidence to guide management of chronic conditions (e.g. diabetes) in people with 
dementia remains limited.25 A recent review of treatment for dementia co-morbidities 
identified six studies, covering depression, osteoporosis, diabetes and cardiovascular 
disease, and only one assessed the impact of treatment on clinical outcomes.25 This lack of 
evidence is particularly problematic for patients within the later stages of dementia when 
treatment targets are likely to change.  
Further research into prescribing practices in dementia remains necessary. Studies are 
needed on prescribing challenges, management of trade-offs between therapeutic benefits 
and adverse outcomes, especially for advanced stages of dementia. Studies should also 
investigate if varying modes of access to healthcare professionals can improve prescribing. 
Meanwhile, improving coordination between primary care and secondary care services may 
contribute to reducing PIP.28,29 Also, medication reviews, including reviews based on 
STOPP/START can reduce PIP and adverse drug events.30 Medication reviews could focus on 
comorbidities associated with the highest PIP risk (e.g. coronary heart disease; depression) 
or on the most common PIP criteria (e.g. prescription of anti-cholinergic drugs to people 
diagnosed with dementia and therapeutic duplication). 
Strengths and weaknesses  
This is one of the largest studies of PIP prevalence in dementia. The ‘real world’ clinical data 
available in CPRD includes both primary and secondary care records, plus accurate 
prescription and dosage information, providing robust data  and allowing comprehensive 
assessment of PIP.15 
STOPP criteria were initially designed for implementation by health care services based on 
the patient’s complete medical history.14 Despite comprehensive access to patient medical 
records there are some barriers to producing a complete picture of prescription practices in 
primary care. Information available was only sufficient to implement 56 of 80 criteria. 
Information is not available for over-the-counter medication. It is impossible to ascertain 
medication adherence from the electronic medical records analysed. Additional limitations 
include possible undiagnosed dementia amongst controls, however this should result in 
estimates with smaller effect sizes. Also, information available did not allow for accurately 
characterising dementia severity, or analysis of how this affects prescribing decisions and 
outcomes. Nonetheless, results produced are consistent with findings from previous studies 
based on the STOPP version 2 criteria, suggesting correct implementation of the criteria.23  
Our observational design does not provide proof of a causal relationship between PIP and 
incidence of AHO; however the associations are in line with findings from previous 
applications of the STOPP criteria to the general population.19 Additional work is necessary 
to test relationships between PIP and AHO in this population. 
Conclusions 
PIP is common in primary care patients living with dementia, and these individuals have 
double the risk of PIP compared to individuals of similar age and gender without a record of 
dementia after accounting for 14 chronic conditions. Risk of PIP was exacerbated by 
multimorbidity, with the most common PIP involving drugs with anti-cholinergic effects and 
therapeutic duplication. This study also showed that prescription of PIP is associated with 
higher rates of Adverse Health Outcomes. This observational evidence highlights the need 
for more research with the goal of optimising medication in this patient group and improve 
clinical outcomes. 
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Tables and Figures 
Table 1: Baseline characteristics – with diagnosis of dementia vs no-diagnosis 
 
Dementia  No dementia Total 
Number 11,175 43,463 54,638 
Age (sd) 84.6 (7.4) 84.3 (7.3) 84.4 (7.3) 
Female (%) 7,328 (65.6) 28,077 (64.6) 35,405 (64.8) 
Quintiles of index of multiple deprivation (%)    
    1 (Lowest) 21.9 26.3 25.8 
    2 20.9 22.7 22.4 
    3 24.4 22.3 22.7 
    4 19.6 17.0 17.6 
    5 (Highest) 13.2 11.7 12.0 
Body Mass Index (%)     
Underweight 6.4 2.8  
Normal 32.9 29.1  
Pre-obesity 22.7 28.3  
Obese 1 8.6 11.8  
Obese 2 & 3 3.1 4.5  
missing 26.3 23.6  
Smoking (%)    
Not smoker 50.1 48.0  
Ex smoke 27.8 30.1  
Currently not smoking 2.0 1.0  
Smoking 7.4 7.8  
missing 12.7 13.2  
Drinking (%)    
Not drinker 24.3 18.1  
Ex-drinker 7.3 3.4  
Drinker 15.7 20.4  
Severe drinker 1.4 2.4  
Heavy drinker 0.7 0.7  
missing 50.6 55.0  
Chronic Conditions (%)    
Atrial fibrillation 2447 (21.9) 7984 (18.4)  
Asthma 1488 (13.3) 5525 (12.7)  
Cancer (5 years) 842 (7.5) 3686 (8.5)  
Coronary heart disease 3074 (27.5) 10450 (24.0)  
Chronic Kidney Disease 3292 (29.5) 12799 (29.4)  
Chronic  Obstructive Pulmonary Disease 1339 (12.0) 4678 (10.8)  
Depression 3481 (31.1) 7599 (17.5)  
Diabetes Mellitus 2 2252 (20.2) 7247 (16.7)  
Epilepsy 448 (4.0) 502 (1.2)  
Heart Failure 1492 (13.4) 4633 (10.7)  
Hypertension 7788 (69.7) 29990 (69.0)  
Hypothyroidism 1633 (14.6) 5888 (13.5)  
Severe mental illness 571 (5.1) 542 (1.2)  
Stroke 2521 (22.6) 5709 (13.1)  
Conditions common in old age (%)    
Delirium 528 (4.7) 441 (1.0)  
Anaemia 393 (3.5) 1221 (2.8)  
Falls 1448 (13.0) 2741 (6.3)  
Fragility fracture 537 (4.8) 1115 (2.6)  
Incontinence 545 (4.9) 677 (1.6)  
Osteoporosis 261 (2.3) 1586 (3.6)  
Osteoarthritis 219 (2.0) 635 (1.5)  
Peptic Ulcer 8 (0.1) 70 (0.2)  
Skin ulcer and pressure sores 271 (2.4) 801 (1.8)  
Health services use    
Visits to GP previous year - average(SD) 8.5 (6.5) 6.1 (5.3)  
Seen by GP at a nursing home (%)  1,075 (9.6)  439 (1.0)   
Referral to geriatric services (%) 572 (5.1) 593 (1.4)  
Referral to cardiology services (%) 154 (1.4) 1173 (2.7)  
  
Table 2:  Prevalence of PIP in patients with dementia versus without recorded dementia - total and by 
chapter of STOPP V2 Criteria.  
STOPP criteria (excluding dementia rules) 
Dementia No dementia 
diff p* # % # % 
At least 1 PIP 8211 73.5 24766 57.0 16.49 <0.01 
A: Indication of medication 3520 31.5 11638 26.8 4.72 <0.01 
B: Cardiovascular System 1103 9.9 3925 9.0 0.84 0.01 
C: Antiplatelet/Anticoagulant Drugs  328 2.9 1325 3.1 -0.11 0.53 
D: Central Nervous System and Psychotropic Drugs 5134 45.9 3519 8.1 37.85 <0.01 
E: Renal System. 1547 13.8 5903 13.6 0.26 0.47 
F: Gastrointestinal System 2336 20.9 6774 15.6 5.32 <0.01 
G: Respiratory System 84 0.8 307 0.7 0.05 0.61 
H: Musculoskeletal System 3116 27.9 12025 27.7 0.22 0.65 
I: Urogenital System 738 6.6 594 1.4 5.24 <0.01 
J. Endocrine System 604 5.4 2447 5.6 -0.23 0.36 
K: Drugs that predictably increase the risk of falls in 
older people 
304 2.7 311 0.7 2.00 <0.01 
L: Analgesic Drugs 606 5.4 2395 5.5 -0.09 0.72 
N: Antimuscarinic/Anticholinergic Drug Burden 1559 14.0 2335 5.4 8.58 <0.01 
* p-value produced using chi2 analysis.  
  
Table 3: Association between diagnosis with a chronic condition and risk of PIP in individuals 
diagnosed with dementia   
 Base adjustment* 
Base adjustment* + 
comorbidities¥ 
 
OR CI% p OR CI% p 
Atrial fibrillation 2.32 2.05-2.61 <0.01 1.61 1.41-1.83 <0.01 
Asthma 1.66 1.45-1.90 <0.01 1.18 1.01-1.37 0.04 
Cancer (5 years) 1.36 1.14-1.61 <0.01 1.19 0.99-1.43 0.06 
Coronary heart disease 3.26 2.90-3.67 <0.01 2.17 1.91-2.46 <0.01 
Chronic Kidney Disease 2.23 2.01-2.48 <0.01 1.66 1.48-1.85 <0.01 
Chronic  Obstructive Pulmonary Disease 2.38 2.02-2.79 <0.01 1.80 1.51-2.14 <0.01 
Depression 2.13 1.92-2.35 <0.01 1.81 1.62-2.01 <0.01 
Diabetes Mellitus 2  2.23 1.97-2.52 <0.01 1.58 1.38-1.80 <0.01 
Epilepsy 1.26 1.0-1.58 0.05 0.93 0.73-1.20 0.59 
Heart Failure 2.53 2.17-2.96 <0.01 1.22 1.02-1.44 0.03 
Hypertension 2.49 2.27-2.72 <0.01 1.67 1.52-1.84 <0.01 
Hypothyroidism 1.31 1.16-1.48 <0.01 1.04 0.91-1.19 0.54 
Severe mental illness 2.41 1.88-3.07 <0.01 2.09 1.62-2.70 <0.01 
Stroke 1.81 1.62-2.03 <0.01 1.34 1.19-1.51 <0.01 
* Base adjustment: age (squared), gender and quintiles of multiple deprivation. 
¥ Conditions: atrial fibrillation, asthma, cancer (5 years), coronary heart disease, chronic kidney 
disease (stage 3 to 5), chronic obstructive pulmonary disease, depression, diabetes mellitus, 
epilepsy, heart failure, hypertension, hypothyroidism, severe mental illness and stroke,  
  
Table 4: Association between PIP and incidence of adverse health outcomes in the follow-up period, 
in individuals diagnosed with dementia.  
 Any one PIM criteria 3 or more PIM criteria 
3 or more PIM criteria & 
3 or more conditions 
 
HR* CI% p HR* CI% p HR* CI% p 
All-cause mortality  1.14 1.02-1.26 0.02 1.17 1.04-1.32 0.01 1.08 0.94-1.24 0.26 
Hospitalisation  1.05 0.97-1.13 0.23 1.15 1.05-1.25 <0.01 1.10 1.0-1.22 0.05 
Delirium 1.23 0.99-1.53 0.06 1.36 1.06-1.74 0.02 1.36 1.02-1.81 0.03 
Anaemia 1.61 1.10-2.38 0.02 1.74 1.12-2.71 0.01 1.67 1.04-2.68 0.03 
Fall 1.37 1.15-1.63 <0.01 1.51 1.23-1.85 <0.01 1.43 1.14-1.81 <0.01 
Fracture 0.92 0.70-1.19 0.51 0.92 0.67-1.26 0.60 0.84 0.58-1.21 0.34 
Incontinence 1.22 0.95-1.56 0.12 1.34 1.01-1.78 0.04 1.25 0.90-1.74 0.18 
Osteoarthritis 1.58 1.01-2.49 0.05 1.49 .89-2.49 0.13 1.27 0.74-2.19 0.38 
Osteoporosis 1.62 1.02-2.57 0.04 1.73 1.05-2.86 0.03 2.58 1.20-5.57 0.02 
Peptic Ulcer 0.38 0.08-1.74 0.21 0.33 .06-1.80 0.20 0.32 0.07-1.45 0.14 
Bed ulcer and pressure 
sores 
1.66 1.12-2.46 0.01 1.87 1.21-2.90 0.01 1.72 1.06-2.81 0.03 
All analyses were adjusted for age, gender, the diagnosis of 14 chronic conditions and prior incidence 
of outcome (except for all-cause mortality) 
*Hazard ratios provided for all-cause mortality and sub-hazard ratios for other outcomes. 
 
